nucleoside analogues or interferon

PreclinicalSmall molecule

nucleoside analogues or interferon is one of 27 small molecule programs targeting Hepatitis B. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatitis BActive, not recruiting

Hepatitis BPreclinical

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Hepatitis B

#DrugCompanyPhaseTrials

Virazole

CConrado Roberto Hoffmann Filho

Phase 3

3 2

Hydronidone

BBeijing Continent Pharmaceutical Co, Ltd.

Phase 3

2 3

Measles Vaccine

GSK

Phase 3

1 4

Hepatitis B Adjuvanted Vaccine

GSK

Phase 3

4 5

Hexaxim

Sanofi

Phase 3

1 6

Vemlidy

Gilead

Preclinical

8 7

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

15 8

Henogen HB Vaccine

HHenogen

Phase 3

1 9

Quinvaxem

CCrucell Holland BV

Phase 3

1 10

Rituxan

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Not yet recruiting

Hepatitis B

NCT05965388

Clinical

Trials by Indication[1]

Hepatitis B1 trial

Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy

Not yet recruiting·WWen-hong Zhang··NCT05965388·5,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for nucleoside analogues or interferon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nucleoside analogues or interferon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nucleoside analogues or interferon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wen-hong Zhang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WWen-hong Zhang

nucleoside analogues or interferon

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Hepatitis B1 trial

References

Drug Info

Quick Facts

Related News